Possible autocrine loop of the epidermal growth factor system in patients with benign prostatic hyperplasia treated with finasteride: a placebo‐controlled randomized study

@article{Trring2002PossibleAL,
  title={Possible autocrine loop of the epidermal growth factor system in patients with benign prostatic hyperplasia treated with finasteride: a placebo‐controlled randomized study},
  author={Niels T{\o}rring and K. M{\O}ller‐Ernst Jensen and L. Lund and John Erik Nielsen and Jens Christian Djurhuus and Steen S Poulsen and E. Nex{\O}},
  journal={BJU International},
  year={2002},
  volume={89}
}
Objective To analyse the expression of the epidermal growth factor (EGF) system in prostate tissue and secretions obtained from patients with benign prostatic hyperplasia (BPH) treated with or without finasteride (which primarily targets the androgen‐sensitive secretory epithelial cells in the prostate, with little effect on basal epithelial and stromal cells). 
Synergistic antiproliferative and apoptotic effects induced by mixed epidermal growth factor receptor inhibitor ZD1839 and nitric oxide donor in human prostatic cancer cell lines
TLDR
Whether the combination of ZD1839 with an agent donating nitric oxide (NO•), sodium nitroprusside (SNP) results in a synergy of anticarcinogenic responses on metastatic prostate cancer (PC) cells is investigated.
Increase in amphiregulin and epiregulin in prostate cancer xenograft after androgen deprivation—impact of specific HER1 inhibition
We investigated the expression of the epidermal growth factor (EGF) network before and after castration in the prostate cancer xenograft CWR22 implanted in nude mice, and examined the effects of
New innovative therapies for benign prostatic hyperplasia: any advance?
  • H. Klingler
  • Medicine, Biology
    Current opinion in urology
  • 2003
TLDR
New insights into prostatic growth and pathogenesis of benign prostatic hyperplasia are presented and herbal drug treatment for lower urinary tract symptoms seems to be more effective than previously thought.
New innovative therapies for benign prostatic hyperplasia: any advance?
TLDR
New insights into prostatic growth and pathogenesis of benign prostatic hyperplasia are presented and a paracrine loop for chronic inflammation with overexpression of interleukin could be identified in the further understanding of prostatic enlargement.
ErbB1 and prostate cancer: ErbB1 activity is essential for androgen‐induced proliferation and protection from the apoptotic effects of LY294002
Androgens play a critical role in proliferation and survival of prostate cancer cells, but the mechanisms leading to these effects are poorly understood. ErbB receptor tyrosine kinases have been
IMMUNOHISTOLOCALIZATION OF c-erbB2 PROTEIN : A PROLIFERATIVE MARKER IN BENIGN PROSTATIC HYPERPLASIA
TLDR
Results of current study and work of previous researchers indicate a lot of controversy over c-erbB-2 immunostaining in benign prostatic hyperplasia, and further study is required to elucidate the precise role played by this protein marker in the benign growth of prostatic tissue.
IMMUNOHISTOLOCALIZATION OF c-erbB-2 PROTEIN: A PROLIFERATIVE MARKER IN BENIGN PROSTATIC HYPERPLASIA
TLDR
Results of current study and work of previous researchers indicate a lot of controversy over c-erbB-2 immunostaining in benign prostatic hyperplasia, and further study is required to elucidate the precise role played by this protein marker in the benign growth of prostatic tissue.
New Advances on Prostate Carcinogenesis and Therapies: Involvement of EGF-EGFR Transduction System
TLDR
Last advances on molecular mechanisms that might be responsible for sustained growth and survival of PC cells are described and emphasis is on intracellular signaling cascades which are involved in the mitogenic and antiapoptotic effects of epidermal growth factor EGF-EGFR system.
ADAM12 is highly expressed in carcinoma-associated stroma and is required for mouse prostate tumor progression
TLDR
The identification of ADAM12 as a novel marker for a subpopulation of stromal cells that are adjacent to epithelial tumor cells in three mouse carcinoma models is described and shown to be essential for tumor development and progression in the W10 mouse model for prostate cancer.
ADAM‐mediated amphiregulin shedding and EGFR transactivation
TLDR
Interactions between the CXCR4 GPCR and the CxCL12 chemokine have been shown to mediate gene transcription and cellular proliferation in non‐transformed and transformed prostate epithelial cells, as well as motility/invasiveness in transformed cells.
...
...

References

SHOWING 1-10 OF 39 REFERENCES
Epidermal growth factor in the rat prostate: Production, tissue content and molecular forms in the different prostatic lobes
TLDR
This investigation was set up to characterize the time and spatial expression of EGF in the rat prostate and found that EGF induces proliferation in prostate epithelial and stromal cells in primary culture.
Urogastrone-epidermal growth factor concentrations in prostatic fluid of normal individuals and patients with benign prostatic hypertrophy.
TLDR
Immunochemical studies failed to show evidence of synthesis within the gland nor could high affinity receptors for the protein be demonstrated in membrane preparations of the gland, and growth factor content of seminal fluid was accounted for by the contribution of prostatic fluid.
The effect of androgen, estrogen, and growth factors on the proliferation of cultured fibroblasts derived from human fetal and adult prostates.
TLDR
It is concluded that EGF, bFGF, and DHT (especially in combination with OH-FLU) increase the proliferation of human prostatic fetal and adult fibroblasts in vitro.
Chronic treatment with epidermal growth factor induces growth of the rat ventral prostate.
TLDR
Prostate tissue showed a significant increase in the volume of the prostate epithelium, the stroma and the lumen following EGF treatment, in a pattern resembling physiological growth of the ventral prostate.
Evidence for atrophy and apoptosis in the prostates of men given finasteride.
TLDR
The results indicate that a progressive decrease in epithelial cell size and function occurs during the first several months in the prostates of men treated with finasteride, and indicates that an increased rate of apoptosis is occurring transiently in these prostates.
Systemic treatment with epidermal growth factor but not insulin-like growth factor I decreases the involution of the prostate in castrated rats
TLDR
Compared with testosterone, the effects of EGF treatment on the prostate involution were moderate, and the effectsof EGF were not related to cellular proliferation.
Developmental and hormonal regulation of transforming growth factor-alpha and epidermal growth factor receptor gene expression in isolated prostatic epithelial and stromal cells.
TLDR
A network of hormonally controlled growth factor-mediated stromal-epithelial interactions is needed to maintain prostate development and function and indicates that regulation of TGF-alpha and EGFR is distinct between the cell types.
Epidermal growth factor receptor-dependent stimulation of amphiregulin expression in androgen-stimulated human prostate cancer cells.
TLDR
It is demonstrated that LNCaP cells express amphiregulin mRNA and peptide and that this expression is elevated by androgenic stimulation, and it is shown that ligand-dependent EGF-R stimulation induces amphire gulin expression and that androgensic effects on amphireGulin synthesis are mediated through this E GF-R pathway.
Expression of transforming growth factor-alpha, epidermal growth factor and the epidermal growth factor receptor in adenocarcinoma of the prostate and benign prostatic hyperplasia.
  • R. Myers, J. E. Kudlow, W. Grizzle
  • Medicine, Biology
    Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • 1993
TLDR
The finding that TGF alpha is expressed only in malignant cells suggests that T GF alpha may represent a locally active autocrine regulator of malignant prostate cells.
...
...